Artivion, Inc. AORT
Updated: 13 Jun 2026
No signal published yet
We already track Artivion and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Artivion, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Artivion free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 18, 2026, Artivion announced the completion of its acquisition of Endospan Ltd. following the U.S. FDA approval of the NEXUS Aortic Arch System. The acquisition involves an upfront payment of $175 million and potential milestone payments based on future commercial performance. This strategic move expands Artivion's portfolio of endovascular solutions for treating complex aortic arch disease.
What Firelda Watch includes for Artivion, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Artivion, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Artivion free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more